GlobeNewswire Inc | Nov 3, 2020 08:01AM EST

November 03, 2020

NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:

29th Annual Credit Suisse Virtual Healthcare ConferenceDate: Tuesday, November 10Presentation Time: 1:15 p.m. ET

H.C. Wainwright & Co. 6th Annual Israel ConferenceDate: Thursday, November 12Presentation Time 11:00 a.m. ET

Jefferies Virtual London Healthcare Conference Date: Tuesday, November 17- Thursday, November 19Management will be available for one-on-one meetings.

Live audio webcasts of the Credit Suisse and H.C. Wainwright presentations will be available under Events and Presentations in the Investors section of the Companys website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena PharmaceuticalsAllena Pharmaceuticals, Inc.is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allenas lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.

Investor ContactHannah DeresiewiczStern Investor Relations, Inc.212-362-1200hannah.deresiewicz@sternir.com

Media ContactAdam DaleyBerry & Company Public Relations 212-253-8881adaley@berrypr.com